|
Our PS-targeting and TNT technologies are supported by extensive published research. For additional information, please reference:
|
PS-Targeting Oncology Publications
- David E. Gerber, Alison T. Stopeck, Lucas Wong, Lee S. Rosen, Philip E. Thorpe, Joseph S. Shan, and Nuhad K. Ibrahim, Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors, Clinical Cancer Research: 2011, 11-1074
- Paul DeRose, Philip E. Thorpe & David E Gerber, Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment. Immunotherapy: 2011, Vol. 3, No. 8, Pages 933-944
- Xianming Huang, Dan Yea and Philip E. Thorpe, Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine. Vaccine: 2011, doi:10.1016/j.vaccine.2011.04.082
- Hogg, R.T., Thorpe, P.E., Gerard, R.D., Retargeting adenoviral vectors to improve gene transfer into tumors, Cancer Gene Therapy: 2010, doi: 10.1038/cgt.2010.78
- Liang, Y., Besch-Williford, C., Benakanakere, I., Thorpe, P.E., and Salman M. Hyder, Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors. Breast Cancer Research and Treatment: 2010, Volume 125, Number 2, 407-420
- Thorpe, P.E., Targeting anionic phospholipids on tumor blood vessels and tumor cells. Thrombosis Research 2010, Apr;125 Suppl 2:S134-7
- He, J. Thorpe, P.E., et al, Antiphosphatidylserine Antibody Combined with Irradiation Damages Tumor Blood Vessels and Induces Tumor Immunity in a Rat Model of Glioblastoma. Clinical Cancer Research, 2009, 15(22):6871–80
- Marconescu A, Thorpe P.E., Coincident exposure of phosphatidylethanolamine and anionic phospholipids on the surface of irradiated cells. Biochemica et Biophysica Acta 2008, 1778(10):2217-24
- Jennewein M., Thorpe, P.E., et al, Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine. Clinical Cancer Research, 2008, 14(5):1377-85
- He, J. Luster, T., Thorpe, P.E., Radiation-Enhanced Vascular Targeting of Human Lung Cancers in Mice with a Monoclonal Antibody That Binds Anionic Phospholipids. Clinical Cancer Research, 2007, 13, 5211
- Beck, A.W., Thorpe, P.E., et al, Combination of a monoclonal antiphosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. International Journal of Cancer, 2005, Volume 118 Issue 10, 2639 - 2643
- Huang, X., Thorpe, P.E., et al, A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice. Cancer Research 2005, 65, 4408-4416
- Ran, S., Thorpe, P.E., et al, Antitumor Effects of a Monoclonal Antibody that Binds Anionic Phospholipids on the Surface of Tumor Blood Vessels in Mice. Clinical Cancer Research 2005, Vol. 11, 1551-1562
- Ran, S., Thorpe, P.E., et al, Increased Exposure of Anionic Phospholipids on the Surface of Tumor Blood Vessels. Cancer Research 2002, 62, 6132-6140
|
|
PS-Targeting Antiviral Publications
- Moody, M.A., Haynes, B.F., et al, Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce β-chemokines. The Journal of Experimental Medicine, 2010, vol. 207 no. 4 763-776
- Soares MM, King SW, Thorpe PE, Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nature Medicine 2008 Dec;14(12):1357-62
|
Cotara Publications
- Sloan, A.E., Hdeib, A. Convection-enhanced delivery of 131I-chTNT-1/B mAB for treatment of high-grade adult gliomas. Expert Opinion on Biological Therapy, 2011, doi:10.1517/14712598.2011.579097
- Jensen, R. et al, Clinical Update: Treatment of Glioblastoma Multiforme with Radiolabeled Antibodies that Target Tumor Necrosis, Current Cancer Therapy Reviews, 2010, Volume 6, Number 1, February 2010 , pp. 13-18
- Shapiro, W.R., Shan, J.S., et al, 2006. (131)I-chTNT-1/B mAb: tumor necrosis therapy for malignant astrocytic glioma. Expert Opinion on Biological Therapy, 2006, 6 (5):539-45
- Patel, S.J., Shan, J.S., et al, Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery, 2005, Jun;56(6):1243-52; discussion 1252-3.
|
|
|
|
|
|